Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Nigericin sodium, the sodium salt of nigericin which is an antibiotic isolated from Streptomyces hygroscopicus, is a cationic ionophore that inhibits Golgi function and suppresses growth of gram positive bacteria. It also prevents viral activation and triggers activation of the NALP3 inflammasome. Nigericin sodium works by acting as an H+, K+, and Pb2+ ionophore.
ln Vitro |
In a dose-dependent way, nigericin (0.1 μM) impeded the growth and colony formation of H460 lung cancer cells. Nigericin prevents H460 lung cancer cells from migrating and from thinning[1]. There appears to be a dual effect of nigericin (0.1–10 nM) on cell volume: a shrinking effect at lower concentrations and a swelling effect at higher ones. At concentrations of 0.1–1 nM, nigerin dramatically lowers cytosolic pH (pHi) and marginally raises PHi at 5 and 10 nM [2]. Nigerin is toxic to S18 and S26 cells, with IC50 values of 2.03±, 0.55 μM, and 4.77±2.35 μM, respectively. In vitro, niridmycin specifically eradicates stem tumors in NPCs. Nirimycin dramatically inhibits S18 and HONE-1 cell migration [3]. HT29 and SW116 cell lines demonstrated fetal toxicity to nigericin, with IC50 values of 12.92±0.25 μMol and 15.86±0.18 μMol, respectively. In typical soft agar assays, nigericin also shows a decreased capacity to form colonies under anchorage-independent circumstances [4].
|
---|---|
ln Vivo |
Volumetric data showed that ngericin (4 mg/kg, ip) exhibited a significant reduction in tumor growth and exhibited good interaction with the chemotherapeutic agent DDP. In vivo, nigericin dramatically lowers Bmi-1. Under nigericin treatment, the CSC content and metastatic potential of NPC cells were partially impacted by overexpression of Bmi-1. The inhibition of nigericin on nasopharyngeal cancer stem cells may be connected to the decline in Bmi-1 [3].
|
References |
[1]. Yakisich JS, et al. Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides. Tumour Biol. 2017 Mar;39(3):1010428317694310
[2]. Bissinger R, et al. Triggering of Suicidal Erythrocyte Death by the Antibiotic Ionophore Nigericin. Basic Clin Pharmacol Toxicol. 2016 May;118(5):381-9 [3]. Deng CC, et al. Nigericin selectively targets cancer stem cells in nasopharyngeal carcinoma. Int J Biochem Cell Biol. 2013 Sep;45(9):1997-2006 [4]. Zhou HM, et al. Suppression of colorectal cancer metastasis by nigericin through inhibition of epithelial-mesenchymal transition. World J Gastroenterol. 2012 Jun 7;18(21):2640-8 |
Molecular Formula |
C40H67NAO11
|
---|---|
Molecular Weight |
746.9432
|
CAS # |
28643-80-3
|
Related CAS # |
Nigericin;28380-24-7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CO[C@@H]1C[C@H](O[C@@]2([C@@H]1C)O[C@@](C[C@H]2C)([C@H]3CC[C@](O3)([C@@H]4O[C@@H]([C@H]5O[C@@](CO)([C@@H](C[C@@H]5C)C)O)C[C@@H]4C)C)C)C[C@H]6CC[C@@H]([C@H]([C@H](C([O-])=O)C)O6)C.[Na+]
|
InChi Key |
MOYOTUKECQMGHE-PDEFJWSRSA-M
|
InChi Code |
InChI=1S/C40H68O11.Na/c1-21-11-12-28(46-33(21)26(6)36(42)43)17-29-18-30(45-10)27(7)40(48-29)25(5)19-38(9,51-40)32-13-14-37(8,49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44,20-41)50-34;/h21-35,41,44H,11-20H2,1-10H3,(H,42,43);/q;+1/p-1/t21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,37-,38-,39-,40+;/m0./s1
|
Chemical Name |
sodium (R)-2-((2R,3S,6R)-6-(((2S,4R,5R,7R,9R,10R)-2-((2S,2'R,3'S,5R,5'R)-5'-((2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-2-yl)-2,3'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-9-methoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-7-yl)methyl)-3-methyltetrahydro-2H-pyran-2-yl)propanoate
|
Synonyms |
Helixin C; Azalomycin M; Nigericin sodium; Polyetherin A
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
Ethanol :≥ 50 mg/mL (~66.94 mM)
DMSO : ~11.76 mg/mL (~15.74 mM ) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.35 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.35 mM) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.35 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3388 mL | 6.6940 mL | 13.3880 mL | |
5 mM | 0.2678 mL | 1.3388 mL | 2.6776 mL | |
10 mM | 0.1339 mL | 0.6694 mL | 1.3388 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.